- Home
- BOOT vs IOVA Comparison
BOOT vs IOVA Comparison
Compare BOOT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- IOVA
- Stock Information
- Founded
- BOOT 1978
- IOVA 2007
- Country
- BOOT United States
- IOVA United States
- Employees
- BOOT N/A
- IOVA N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOOT Consumer Discretionary
- IOVA Health Care
- Exchange
- BOOT Nasdaq
- IOVA Nasdaq
- Market Cap
- BOOT 4.8B
- IOVA 771.4M
- IPO Year
- BOOT 2014
- IOVA N/A
- Fundamental
- Price
- BOOT $160.27
- IOVA $1.75
- Analyst Decision
- BOOT Strong Buy
- IOVA Buy
- Analyst Count
- BOOT 12
- IOVA 10
- Target Price
- BOOT $176.17
- IOVA $12.22
- AVG Volume (30 Days)
- BOOT 617.3K
- IOVA 11.7M
- Earning Date
- BOOT 08-06-2025
- IOVA 08-07-2025
- Dividend Yield
- BOOT N/A
- IOVA N/A
- EPS Growth
- BOOT 22.50
- IOVA N/A
- EPS
- BOOT 5.88
- IOVA N/A
- Revenue
- BOOT $1,911,104,000.00
- IOVA $212,679,000.00
- Revenue This Year
- BOOT $14.33
- IOVA $86.62
- Revenue Next Year
- BOOT $12.95
- IOVA $69.95
- P/E Ratio
- BOOT $27.23
- IOVA N/A
- Revenue Growth
- BOOT 14.64
- IOVA 11070.12
- 52 Week Low
- BOOT $86.17
- IOVA $1.64
- 52 Week High
- BOOT $176.64
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- BOOT 56.73
- IOVA 38.67
- Support Level
- BOOT $151.58
- IOVA $1.67
- Resistance Level
- BOOT $167.36
- IOVA $1.82
- Average True Range (ATR)
- BOOT 5.24
- IOVA 0.12
- MACD
- BOOT -1.74
- IOVA -0.01
- Stochastic Oscillator
- BOOT 61.72
- IOVA 13.64
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.